First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma

Bone Marrow Transplant. 2017 Feb;52(2):310-312. doi: 10.1038/bmt.2016.271. Epub 2016 Nov 28.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Autografts
  • Disease-Free Survival
  • Hematopoietic Stem Cell Mobilization*
  • Hodgkin Disease* / blood
  • Hodgkin Disease* / mortality
  • Hodgkin Disease* / therapy
  • Humans
  • Middle Aged
  • Peripheral Blood Stem Cell Transplantation*
  • Stem Cells
  • Survival Rate